CRISPR/Cas9n沉默miR-17-92可恢复未分化甲状腺癌细胞分化
该研究在KTC2未分化甲状腺癌细胞系中用CRISPR/Cas9n沉默miR-17-92基因,在正常甲状腺细胞中过表达该簇或单个miRNA。结果显示沉默miR-17-92促进甲状腺分化标志物表达并抑制迁移增殖,过表达则损伤分化并促癌,提示靶向miR-17-92可能恢复NIS表达。
要点
- CRISPR/Cas9n沉默miR-17-92可促进KTC2未分化甲状腺癌细胞分化标志物表达
- 沉默miR-17-92可抑制KTC2细胞迁移和增殖并恢复TGF-β信号反应性
- 正常甲状腺细胞过表达miR-17-92会损伤分化并增加迁移
核心结论
- miR-17-92是甲状腺滤泡细胞分化的强效调节因子,靶向该簇可能恢复侵袭性甲状腺癌细胞分化和NIS表达。
研究设计与样本
- 在KTC2未分化甲状腺癌细胞系中用CRISPR/Cas9n介导基因组编辑沉默miR-17-92基因。
- 在PCCl3正常甲状腺细胞中过表达miR-17-92簇或单个miRNA以评估对分化和功能的影响。
主要发现
- CRISPR/Cas9n编辑miR-17-92簇促进KTC2细胞中NIS、甲状腺过氧化物酶、甲状腺球蛋白、PAX8和NKX2-1表达。
- 沉默miR-17-92抑制KTC2细胞迁移和增殖,并恢复对转化生长因子β(TGF-β)信号通路的反应性。
- 在正常甲状腺滤泡细胞中诱导miR-17-92强烈损害甲状腺分化,通过阻断TGF-β信号和增加细胞迁移产生促癌效应。
临床怎么用
- 靶向miR-17-92可能作为恢复侵袭性甲状腺癌细胞分化和NIS表达的潜在分子策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Loss of the expression of thyroid differentiation markers such as sodium iodide symporter (NIS) and, consequently, radioiodine refractoriness is observed in aggressive papillary thyroid cancer and anaplastic thyroid cancer (ATC) that may harbor the BRAFV600E mutation. Activation of the BRAFV600E oncogene in thyroid follicular cells induces the expression of the miR-17-92 cluster that comprises seven mature microRNAs (miRNAs). miRNAs are a class of endogenous small RNAs (∼22 nt) that regulate gene expression post-transcriptionally. Indeed, miR-17-92 is overexpressed in ATC, and in silico prediction shows the potential targeting of thyroid transcription factors and tumor suppressor pathways. In this study, we aimed to investigate the role of the miR-17-92 cluster in thyroid cell differentiation and function. Methods:miR-17-92 silencing was performed using CRISPR/Cas9n-guided genomic editing of the miR-17-92 gene in the KTC2 ATC cell line, and miR-17-92 cluster or individual miRNAs were overexpressed in PCCl3 thyroid cells to evaluate the influence in thyroid cell differentiation and cell function. Results: In this study, we demonstrate that CRISPR/Cas9n gene editing of the miR-17-92 cluster results in promotion of thyroid follicular cell differentiation (NIS, thyroperoxidase, thyroglobulin, PAX8, and NKX2-1 expression) in the KTC2 ATC cell line and inhibits cell migration and proliferation by restoring transforming growth factor beta (TGF-β) signaling pathway responsiveness. Moreover, induction of the miR-17-92 cluster in normal thyroid follicular cells strongly impairs thyroid differentiation and induces a pro-oncogenic effect by blocking TGF-β signaling and increasing cell migration. Conclusions:miR-17-92 is a potent regulator of thyroid follicular cell differentiation, and CRISPR/Cas9n-mediated editing of the miR-17-92 gene efficiently blocks miR-17-92 expression in the KTC2 ATC cell line, resulting in improvement of thyroid differentiation. Thus, targeting miR-17-92 could provide a potential molecular approach to restoring thyroid cell differentiation and NIS expression in aggressive thyroid cancer.
引用
- Fuziwara CS, Saito KC, Kimura ET, et al. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer. Thyroid. 2019. PMID: 31578932. doi:10.1089/thy.2018.0601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。